Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

John H Stone, M.D.

Co-Author

This page shows the publications co-authored by John Stone and Sebastian Unizony.
Connection Strength

7.603
  1. Treatment failure in giant cell arteritis. Ann Rheum Dis. 2021 11; 80(11):1467-1474.
    View in: PubMed
    Score: 0.939
  2. Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations. Arthritis Res Ther. 2021 01 06; 23(1):8.
    View in: PubMed
    Score: 0.914
  3. Inpatient complications in patients with giant cell arteritis: decreased mortality and increased risk of thromboembolism, delirium and adrenal insufficiency. Rheumatology (Oxford). 2015 Aug; 54(8):1360-8.
    View in: PubMed
    Score: 0.607
  4. Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2015 Feb; 67(2):535-44.
    View in: PubMed
    Score: 0.606
  5. Design of the tocilizumab in giant cell arteritis trial. Int J Rheumatol. 2013; 2013:912562.
    View in: PubMed
    Score: 0.534
  6. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken). 2012 Nov; 64(11):1720-9.
    View in: PubMed
    Score: 0.518
  7. The Effects of Treatment on Body Mass Index in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial. Rheumatol Ther. 2022 Apr; 9(2):497-508.
    View in: PubMed
    Score: 0.244
  8. New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. Rheumatology (Oxford). 2021 Oct 29.
    View in: PubMed
    Score: 0.242
  9. Reply. Arthritis Care Res (Hoboken). 2021 07; 73(7):1059-1060.
    View in: PubMed
    Score: 0.236
  10. Reply. Arthritis Care Res (Hoboken). 2021 07; 73(7):1057-1058.
    View in: PubMed
    Score: 0.235
  11. Ustekinumab for the Treatment of Giant Cell Arteritis. Arthritis Care Res (Hoboken). 2021 06; 73(6):893-897.
    View in: PubMed
    Score: 0.235
  12. Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial. Semin Arthritis Rheum. 2021 04; 51(2):469-476.
    View in: PubMed
    Score: 0.232
  13. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020 12 10; 383(24):2333-2344.
    View in: PubMed
    Score: 0.225
  14. Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. Arthritis Rheumatol. 2019 08; 71(8):1329-1338.
    View in: PubMed
    Score: 0.206
  15. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017 07 27; 377(4):317-328.
    View in: PubMed
    Score: 0.180
  16. Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Care Res (Hoboken). 2017 07; 69(7):1004-1010.
    View in: PubMed
    Score: 0.179
  17. Temporal Trends of Venous Thromboembolism Risk Before and After Diagnosis of Giant Cell Arteritis. Arthritis Rheumatol. 2017 01; 69(1):176-184.
    View in: PubMed
    Score: 0.173
  18. An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy. Ann Rheum Dis. 2017 May; 76(5):898-905.
    View in: PubMed
    Score: 0.172
  19. Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets. Arthritis Rheumatol. 2016 12; 68(12):2945-2952.
    View in: PubMed
    Score: 0.172
  20. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis. 2016 Jun; 75(6):1166-9.
    View in: PubMed
    Score: 0.160
  21. Challenging mimickers of primary systemic vasculitis. Rheum Dis Clin North Am. 2015; 41(1):141-60, ix.
    View in: PubMed
    Score: 0.151
  22. New treatment strategies in large-vessel vasculitis. Curr Opin Rheumatol. 2013 Jan; 25(1):3-9.
    View in: PubMed
    Score: 0.131
  23. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore). 2012 Jan; 91(1):57-66.
    View in: PubMed
    Score: 0.122
  24. Nationwide Trends in Hospitalizations and In-Hospital Mortality in Granulomatosis With Polyangiitis (Wegener's). Arthritis Care Res (Hoboken). 2017 06; 69(6):915-921.
    View in: PubMed
    Score: 0.044
  25. Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial. Semin Arthritis Rheum. 2017 04; 46(5):657-664.
    View in: PubMed
    Score: 0.043
  26. Improved survival in granulomatosis with polyangiitis: A general population-based study. Semin Arthritis Rheum. 2016 Feb; 45(4):483-9.
    View in: PubMed
    Score: 0.039
  27. Ocular inflammatory disease in patients with polymyalgia rheumatica: A case series and review of the literature. Clin Rheumatol. 2016 Jan; 35(1):251-8.
    View in: PubMed
    Score: 0.036
  28. Acute fibrinous and organizing pneumonia in systemic lupus erythematosus: a case report and review of the literature. Pathol Int. 2010 Nov; 60(11):755-9.
    View in: PubMed
    Score: 0.028
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.